NEW ORLEANS – Profusa, which creates bioengineered sensors, has developed an in-body sensor capable of continuous, long-term monitoring of body chemistry and streaming the data to a mobile phone and the cloud for personal and medical use. “Based on our ongoing studies, tissue-integrated sensor technology has the potential to enable wearables to live up to the promise of personalized medicine, revolutionizing the management of health in wellness and disease,” said Natalie Wisniewski, chief technology officer and co-founder of Profusa, in a statement. The Profusa researchers are developing a family of tiny biosensors composed of a tissue-like hydrogel that are placed under the skin with a single injection. They work fully integrated within the body’s tissue—without any metal device or electronics—overcoming the body’s attempts to reject it. To date, the injected biosensors have functioned for as long as four years. The Lumee Oxygen Platform, the first medical application of the biosensor technology, was approved for sale last year in Europe, and is helping wound-healing specialists track oxygen in the lower extremities of patients undergoing treatment for chronic limb ischemia. In addition to measuring oxygen, the Profusa team is developing biosensors for continuous monitoring of glucose, lactate, carbon dioxide and other molecules.
You are here: / / Profusa develops in-body continuous sensor